Data:2009-12-12 2:34
Category: Money tips Release Date: 2007-08-04
Pien Tze Huang (600,436 market, information, reviews, search) the original product ex-factory price is 140 yuan / tablets, export price increases by 11%, and price increases before the company's product exports in 2007 of approximately: 150 million , accounting for about 40% of the total output of Pien Tze Huang, Pien Tze Huang price increases in 2007 after the company's exports will be increased to 167 million, then it will produce the company's full-year net profit growth of around 5%.
Product price increases the company's sales growth will not pose any effect, which is monopolized by the product determined; adjustment of export products will be further follow-up sales of domestic products will be adjusted, but the adjustment should be 8 % of; the future of the company will be more frequent price adjustment may be because the current prices are relatively low, relatively speaking. Company's products have absolute autonomy of pricing power. The company's future performance, high-growth can be expected: 1, the company has a clear product dominance and brand advantages, the new management into the long-term development of enterprises will have significant role in promoting; 2, the future implementation of the policy will increase the price directly enhance corporate profitability level; generic drugs, cosmetics, Pien Tze Huang Capsule listing, Pien Tze Huang to start and so the domestic market will drive growth.
Ping An Securities analyst Song Dong Du expects the company's 2006 earnings per share 0.64 yuan 07,08-year earnings per share were 0.88 yuan and 1.12 yuan, respectively, 07/08 years, price-earnings ratio of 31 times and 24 times, that the company has long-term investment value, for such brands have a monopoly advantages of Chinese medicine businesses, valuation should be "Maotai" line. Maintain long-term "recommended" investment rating.
